Oculis Holding (OCS) said Thursday that it has completed enrollment in two late-stage trials of OCS-01 eye drops in diabetic macular edema.
The trials, which enrolled more than 800 patients from the US and other countries, will assess the eye drops' efficacy and safety after 52 weeks of treatment, the company said.
The company said topline data from both trials is expected in Q2 of next year, followed by the submission of a new drug application.
Oculis shares were up 5.7% in recent premarket activity Thursday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。